aTyr Pharma Inc expected to post a loss of 19 cents a share - Earnings Preview

aTyr Pharma

28/04/2025 12:35

aTyr Pharma Inc ATYR.OQ ATYR.O is expected to show a fall in quarterly revenue when it reports  results on April 30 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for aTyr Pharma Inc is for a loss of 19 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 0.8% in the last three months. ​

Wall Street's median 12-month price target for aTyr Pharma Inc is $16.50​, above​ its last closing price of $3.35. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.21
-0.23
-0.18
Beat
20.4
Sep. 30 2024
-0.22
-0.22
-0.23
Missed
-4.5
Jun. 30 2024
-0.24
-0.24
-0.23
Beat
3.4​
Mar. 31 2024
-0.25
-0.24
-0.23
Beat
2.5
​​Dec. 31 2023
-0.24
-0.25
Missed
-5
Sep. 30 2023
-0.22
-0.23
-0.20
Beat
11.5​
Jun. 30 2023
-0.28
-0.28
-0.22
Beat
21
Mar. 31 2023
-0.40
-0.40
-0.29
Beat
27.2

This summary was machine generated April 28 at 11:35 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)